Abstract:DNA polymerase delta 1 catalytic subunit (POLD1) plays a vital role in genomic copy with high fidelity and DNA damage repair processes. However, the prognostic value of POLD1 and its relationship with tumor immunity in clear cell renal cell carcinoma (ccRCC) remains to be further explored. Transcriptional data sets and clinical information were obtained from the TCGA, ICGC, and GEO databases. Differentially expressed genes (DEGs) were derived from the comparison between the low and high POLD1 expression groups in the TCGA-KIRC cohort. KEGG and gene ontology (GO) analyses were performed for those DEGs to explore the potential influence of POLD1 on the biological behaviors of ccRCC. The prognostic clinical value and mutational characteristics of patients were described and analyzed according to the POLD1 expression levels. TIMER and TISIDB databases were utilized to comprehensively investigate the potential relevance between the POLD1 levels and the status of the immune cells, as well as the tumor infiltration of immune cells. In addition, RT-qPCR, Western blot, immunohistochemistry and several functional and animal experiments were performed for clinical, in vitro and in vivo validation. POLD1 was highly expressed in a variety of tumors including ccRCC, and further verified in a validation cohort of 60 ccRCC samples and in vitro cell line experiments. POLD1 expression levels in the ccRCC samples were associated with various clinical characteristics including pathologic tumor stage and histologic grade. ccRCC patients with high POLD1 expression have poor clinical outcomes and exhibit a higher rate of somatic mutations than those with low POLD1 expression. Cox regression analysis also showed that POLD1 could act as a potential independent prognostic biomarker. The DEGs associated with POLD1 were significantly enriched in the immunity-related pathways. Moreover, further immune infiltration analysis indicated that high POLD1 expression was associated with high NK CD56bright cells, Treg cells, and myeloid-derived suppressor cells' (MDSCs) infiltration scores, as well as their marker gene sets of immune cell status. Meanwhile, POLD1 exhibited resistance to various drugs when highly expressed. Finally, the knockdown of POLD1 inhibited the proliferation and migration, and promoted the apoptosis of ccRCC cells in vitro and in vivo, as well as influenced the activation of oncogenic signaling. Our current study demonstrated that POLD1 is a potential prognostic biomarker for ccRCC patients. It might create a tumor immunosuppressive microenvironment and inhibit the susceptibility to ferroptosis leading to a poor prognosis.

Prognostic Impact of ALDH1 Expression in Transitional Cell Carcinoma of the Renal Pelvis

The Effect of WT1 Expression on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia

The expression and clinical significance of ALDH2 in clear renal cell carcinoma

Prognostic and immunological role of acetaldehyde dehydrogenase 1B1 in human tumors: A pan-cancer analysis

Aldehyde Dehydrogenase 3A1 is Robustly Upregulated in Gastric Cancer Stem-Like Cells and Associated with Tumorigenesis.

Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation

Expression Of Aldh1 And Tgf Beta 2 In Benign And Malignant Breast Tumors And Their Prognostic Implications

The Prognostic Roles of Circulating ALDH1(+) Tumor Cell in the Patients with Non-Small Cell Lung Cancer

The Role of LGR5 and ALDH1A1 in Non-Small Cell Lung Cancer: Cancer Progression and Prognosis

Nuclear aldehyde dehydrogenase 1A1 (ALDH1A1) expression is a favorable prognostic indicator in colorectal carcinoma.

POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma

Prognostic Value of ALDH1 and Nestin in Advanced Cancer: a Systematic Meta-Analysis with Trial Sequential Analysis

Role of ALDH1 in the prognosis of esophageal cancer and its relationship with tumor microenvironment

Cancer Stem Cell Marker ALDH1 Expression is Associated with Lymph Node Metastasis and Poor Survival in Esophageal Squamous Cell Carcinoma: a Study from High Incidence Area of Northern China.

Clinicopathological Significance of ALDH1A1 in Lung, Colorectal, and Breast Cancers: a Meta-Analysis.

Transcriptional Expressions of ALDH1A1/B1 as Independent Indicators for the Survival of Thyroid Cancer Patients

ALDH1A3 correlates with luminal phenotype in prostate cancer.

Aldehyde Dehydrogenase 1 Expression Correlates with Clinicopathologic Features of Patients with Breast Cancer: A Meta-Analysis

ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients

Aldehyde dehydrogenase 1 is a tumor stem cell-Associated marker in lung cancer

ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription